OX40 agonists for cancer treatment: a patent review.
Jorge CebadaPerez-Santos MartinBandala CindyEleazar Lara-PadillaIrma Herrera-CamachoNora Hilda Rosas-MurrietaLourdes Millán-Perez PeñaEduardo MonjarazAmira FloresMaricruz Anaya-RuizPublished in: Expert opinion on therapeutic patents (2020)
An increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. United States was the leader in generating patents, followed by China and England. Major pharmaceutical companies have at least one anti-OX40 agonist, MEDI6469 and MEDI-0562 (AstraZeneca), PF-04518600 (Pfizer), GSK3174998 (GlaxoSmithKline), BMS-986,178 (Bristol-Myers Squibb) and MOXR0916 (Roche), which represent 68% of clinical trials conducted with OX40 agonists.